1
|
Hu Y, Wang Y, Yang F, Liu D, Lu G, Li S, Wei Z, Shen X, Jiang Z, Zhao Y, Pang Q, Song B, Shi Z, Shafique S, Zhou K, Chen X, Su W, Jian J, Tang K, Liu T, Zhu Y. Flexible Organic Photovoltaic-Powered Hydrogel Bioelectronic Dressing With Biomimetic Electrical Stimulation for Healing Infected Diabetic Wounds. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024; 11:e2307746. [PMID: 38145346 PMCID: PMC10933690 DOI: 10.1002/advs.202307746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 11/28/2023] [Indexed: 12/26/2023]
Abstract
Electrical stimulation (ES) is proposed as a therapeutic solution for managing chronic wounds. However, its widespread clinical adoption is limited by the requirement of additional extracorporeal devices to power ES-based wound dressings. In this study, a novel sandwich-structured photovoltaic microcurrent hydrogel dressing (PMH dressing) is designed for treating diabetic wounds. This innovative dressing comprises flexible organic photovoltaic (OPV) cells, a flexible micro-electro-mechanical systems (MEMS) electrode, and a multifunctional hydrogel serving as an electrode-tissue interface. The PMH dressing is engineered to administer ES, mimicking the physiological injury current occurring naturally in wounds when exposed to light; thus, facilitating wound healing. In vitro experiments are performed to validate the PMH dressing's exceptional biocompatibility and robust antibacterial properties. In vivo experiments and proteomic analysis reveal that the proposed PMH dressing significantly accelerates the healing of infected diabetic wounds by enhancing extracellular matrix regeneration, eliminating bacteria, regulating inflammatory responses, and modulating vascular functions. Therefore, the PMH dressing is a potent, versatile, and effective solution for diabetic wound care, paving the way for advancements in wireless ES wound dressings.
Collapse
Affiliation(s)
- Yi‐Wei Hu
- Health Science CenterNingbo UniversityNingbo315211P. R. China
- Orthopaedic Oncology Center of Changzheng HospitalNaval Medical UniversityShanghai200003P. R. China
| | - Yu‐Heng Wang
- Faculty of Electrical Engineering and Computer ScienceNingbo UniversityNingbo315211P. R. China
- State Key Laboratory of Electrical Insulation and Power EquipmentXi'an Jiaotong UniversityXi'an710049P. R. China
- CAS Key Laboratory of Nanosystem and Hierarchical FabricationNational Center for Nanoscience and TechnologyUniversity of Chinese Academy of SciencesBeijing100049P. R. China
| | - Fang Yang
- Health Science CenterNingbo UniversityNingbo315211P. R. China
| | - Ding‐Xin Liu
- State Key Laboratory of Electrical Insulation and Power EquipmentXi'an Jiaotong UniversityXi'an710049P. R. China
| | - Guang‐Hao Lu
- State Key Laboratory of Electrical Insulation and Power EquipmentXi'an Jiaotong UniversityXi'an710049P. R. China
| | - Sheng‐Tao Li
- State Key Laboratory of Electrical Insulation and Power EquipmentXi'an Jiaotong UniversityXi'an710049P. R. China
| | - Zhi‐Xiang Wei
- CAS Key Laboratory of Nanosystem and Hierarchical FabricationNational Center for Nanoscience and TechnologyUniversity of Chinese Academy of SciencesBeijing100049P. R. China
| | - Xiang Shen
- The Research Institute of Advanced TechnologiesNingbo UniversityNingbo315211P. R. China
| | - Zhuang‐De Jiang
- State Key Laboratory for Manufacturing Systems EngineeringXi'an Jiaotong UniversityXi'an710049P. R. China
| | - Yi‐Fan Zhao
- State Key Laboratory for Manufacturing Systems EngineeringXi'an Jiaotong UniversityXi'an710049P. R. China
| | - Qian Pang
- Health Science CenterNingbo UniversityNingbo315211P. R. China
| | - Bai‐Yang Song
- Health Science CenterNingbo UniversityNingbo315211P. R. China
| | - Ze‐Wen Shi
- Health Science CenterNingbo UniversityNingbo315211P. R. China
| | - Shareen Shafique
- School of Physical Science and TechnologyNingbo UniversityNingbo315211P. R. China
| | - Kun Zhou
- Shenzhen Institute of Aggregate Science and TechnologyThe Chinese University of Hong Kong ShenzhenShenzhen518172P. R. China
| | - Xiao‐Lian Chen
- Printable Electronics Research Center & Nano‐Device and Materials DivisionSuzhou Institute of Nano‐Tech and Nano‐BionicsNano Chinese Academy of SciencesSuzhou215123P. R. China
| | - Wen‐Ming Su
- Printable Electronics Research Center & Nano‐Device and Materials DivisionSuzhou Institute of Nano‐Tech and Nano‐BionicsNano Chinese Academy of SciencesSuzhou215123P. R. China
| | - Jia‐Wen Jian
- Faculty of Electrical Engineering and Computer ScienceNingbo UniversityNingbo315211P. R. China
| | - Ke‐Qi Tang
- Institute of Mass SpectrometrySchool of Material Science and Chemical EngineeringNingbo UniversityNingbo315211P. R. China
| | - Tie‐Long Liu
- Orthopaedic Oncology Center of Changzheng HospitalNaval Medical UniversityShanghai200003P. R. China
| | - Ya‐Bin Zhu
- Health Science CenterNingbo UniversityNingbo315211P. R. China
| |
Collapse
|
2
|
Lan G, Song Q, Luan Y, Cheng Y. Targeted strategies to deliver boron agents across the blood-brain barrier for neutron capture therapy of brain tumors. Int J Pharm 2024; 650:123747. [PMID: 38151104 DOI: 10.1016/j.ijpharm.2023.123747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/21/2023] [Accepted: 12/23/2023] [Indexed: 12/29/2023]
Abstract
Boron neutron capture therapy (BNCT), as an innovative radiotherapy technology, has demonstrated remarkable outcomes when compared to conventional treatments in the management of recurrent and refractory brain tumors. However, in BNCT of brain tumors, the blood-brain barrier is a main stumbling block for restricting the transport of boron drugs to brain tumors, while the tumor targeting and retention of boron drugs also affect the BNCT effect. This review focuses on the recent development of strategies for delivering boron drugs crossing the blood-brain barrier and targeting brain tumors, providing new insights for the development of efficient boron drugs for the treatment of brain tumors.
Collapse
Affiliation(s)
- Gongde Lan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Qingxu Song
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China
| | - Yuxia Luan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Yufeng Cheng
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
| |
Collapse
|
3
|
Monti Hughes A, Hu N. Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies. Cancers (Basel) 2023; 15:4091. [PMID: 37627119 PMCID: PMC10452654 DOI: 10.3390/cancers15164091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/27/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina
- National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan;
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan
| |
Collapse
|
4
|
Xiang J, Ma L, Tong J, Zuo N, Hu W, Luo Y, Liu J, Liang T, Ren Q, Liu Q. Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy. Front Med (Lausanne) 2023; 10:1199881. [PMID: 37324130 PMCID: PMC10267362 DOI: 10.3389/fmed.2023.1199881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/15/2023] [Indexed: 06/17/2023] Open
Abstract
Boron neutron capture therapy (BNCT) induces intracellular nuclear reaction to destroy cancer cells during thermal neutron irradiation. To selectively eliminate cancer cells but avoid harmful effects on normal tissues, novel boron-peptide conjugates with angiopep-2, namely ANG-B, were constructed and evaluated in preclinical settings. Boron-peptide conjugates were synthesized using solid-phase peptide synthesis, and the molecular mass was validated by mass spectrometry afterwards. Boron concentrations in 6 cancer cell lines and an intracranial glioma mouse model after treatments were analyzed by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Phenylalanine (BPA) was tested in parallel for comparison. In vitro treatment with boron delivery peptides significantly increased boron uptake in cancer cells. BNCT with 5 mM ANG-B caused 86.5% ± 5.3% of clonogenic cell death, while BPA at the same concentration caused 73.3% ± 6.0% clonogenic cell death. The in vivo effect of ANG-B in an intracranial glioma mouse model was evaluated by PET/CT imaging at 31 days after BNCT. The mouse glioma tumours in the ANG-B-treated group were shrunk by 62.9% on average, while the BPA-treated tumours shrank by only 23.0%. Therefore, ANG-B is an efficient boron delivery agent, which has low cytotoxicity and high tumour-to-blood ratio. Based on these experimental results, we expected that ANG-B may leverage BNCT performance in clinical applications in future.
Collapse
Affiliation(s)
- Jing Xiang
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, China
| | - Lin Ma
- Department of Stomatology, General Hospital, Shenzhen University, Shenzhen, Guangdong, China
| | - Jianfei Tong
- Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, China
- Spallation Neutron Source Science Center, Dongguan, China
| | - Nan Zuo
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
- Department of Stomatology, The First Hospital, Harbin Medical University, Harbin, China
| | - Weitao Hu
- School of Stomatology, Hangzhou Normal University, Hangzhou, Zhejiang, China
| | - Yupeng Luo
- School of Stomatology, Shenzhen University, Shenzhen, Guangdong, China
| | - Junqi Liu
- Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Tianjiao Liang
- Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, China
- Spallation Neutron Source Science Center, Dongguan, China
| | - Qiushi Ren
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, China
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
| | - Qi Liu
- Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China
- International Cancer Center, Shenzhen University School of Medicine, Shenzhen University, Shenzhen, Guangdong, China
| |
Collapse
|
5
|
Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation in BNCT of Brain-Tumor-Model Rats—Ex Vivo Imaging of BPA Using MALDI Mass Spectrometry Imaging. Life (Basel) 2022; 12:life12111786. [DOI: 10.3390/life12111786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/27/2022] [Accepted: 10/28/2022] [Indexed: 11/09/2022] Open
Abstract
The blood–brain barrier (BBB) is likely to be intact during the early stages of brain metastatic melanoma development, and thereby inhibits sufficient drug delivery into the metastatic lesions. Our laboratory has been developing a system for boron drug delivery to brain cells via cerebrospinal fluid (CSF) as a viable pathway to circumvent the BBB in boron neutron capture therapy (BNCT). BNCT is a cell-selective cancer treatment based on the use of boron-containing drugs and neutron irradiation. Selective tumor targeting by boron with minimal normal tissue toxicity is required for effective BNCT. Boronophenylalanine (BPA) is widely used as a boron drug for BNCT. In our previous study, we demonstrated that application of the CSF administration method results in high BPA accumulation in the brain tumor even with a low dose of BPA. In this study, we evaluate BPA biodistribution in the brain following application of the CSF method in brain-tumor-model rats (melanoma) utilizing matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI). We observed increased BPA penetration to the tumor tissue, where the color contrast on mass images indicates the border of BPA accumulation between tumor and normal cells. Our approach could be useful as drug delivery to different types of brain tumor, including brain metastases of melanoma.
Collapse
|